Brief: Vaccitech Announces Update On VTP-300 Trial

Barinthus Biotherapeutics

22/06/2022 11:43

June 22 (Reuters) - Vaccitech PLC  VACC.O :
    * VACCITECH’S VTP-300 INDUCED SUSTAINED REDUCTIONS OF
SURFACE
ANTIGEN IN PATIENTS WITH CHRONIC HEPATITIS B BOTH AS A
MONOTHERAPY AND IN COMBINATION WITH A SINGLE LOW DOSE OF
ANTI-PD-1
    * VACCITECH PLC - NO TREATMENT-RELATED SERIOUS ADVERSE
EVENTS AND
INFREQUENT TRANSIENT TRANSAMINITIS RELATED TO VTP-300
    * VACCITECH PLC - MEANINGFUL, DURABLE REDUCTIONS OF
HEPATITIS B
SURFACE ANTIGEN (HBSAG) WERE SEEN IN SOME PATIENTS WHO RECEIVED
VTP-300

Source text for Eikon:  ID:nGNX4FlNbK 
Further company coverage:  VACC.O 

 ((Reuters.Briefs@thomsonreuters.com;))